Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Halliburton Company — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Halliburton Company trades at $35.5 (market cap $29.59B). The key difference: Halliburton Company is far larger — about 3.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Halliburton Company pays a 1.92% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HAL | |
|---|---|---|
Market Cap | $8.04B | $29.59B |
Sector | Health | Energy |
52-Week High | $339.75 | $42.98 |
52-Week Low | $241.71 | $20.50 |
Enterprise Value | $7.85B | $35.67B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Halliburton (HAL) trades at $35.21, up 2.38% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a major contract win offshore Suriname highlight operational strength, though net income declined in 2025. The stock shows solid profitability with a 6.95% net margin and 14.56% ROE, supported by positive cash flow trends into 2026.
The outlook remains positive given analyst targets near $44.78 and ongoing energy sector tailwinds, but risks include oil price volatility and execution challenges. Earnings growth and contract execution are key catalysts for further upside, balancing macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
